Categories AlphaGraphs, Earnings, Leisure & Entertainment
ATVI Earnings: Activision Blizzard Q4 revenue up 8%, earnings decline
Video game publisher Activision Blizzard, Inc. (NASDAQ: ATVI) has announced results for the fourth quarter of 2022, reporting a sharp decline in adjusted earnings, despite an increase in revenues.
Fourth-quarter net revenues increased 8% from last year to $2.33 billion. At $3.57 billion, total bookings were up 43% during the three-month period.
Meanwhile, net income decreased to $403 million or $0.51 per share in the December quarter from $564 million or $0.72 per share in the same period of last year. Adjusted profit decreased by 23% to $0.78 per share.
“We look forward to a historic year, as we work toward merging with Microsoft. This merger will enable us to better serve our players, create greater opportunities for our employees, and allow us to succeed in an increasingly competitive global gaming industry,” said Activision’s CEO Bobby Kotick.
Prior Performance
_________________________________________________________________________________________________________________
Stocks you may like:
International Business Machines Corp. (IBM) Stock
_________________________________________________________________________________________________________________
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs